A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid) In Patients With Mantle-Cell Lymphoma.
Phase of Trial: Phase III
Latest Information Update: 02 May 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms RENEW
- 06 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by German Clinical Trials Register.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003817).
- 28 Apr 2012 Planned number of patients changed from 382 to 450 as reported by European Clinical Trials Database record.